About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19

NCT04477993·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Vanderson Geraldo Rocha

Age

18–95

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Patients hospitalized with SARS-CoV-2 pneumonia confirmed by RT-PCR or serology (IgA);
PaO2/FiO2 \< 300 (not fully explained by heart failure or volume overload) or SpO2 \< 90% on room air.

You may not be if

Symptom onset \> 14 days;
Neutrophil count \< 1,000/mm3;
Platelets \< 50,000/mm3;
ICU care at enrollment;
On invasive mechanical ventilation at enrollment;
Current use of experimental therapy for COVID-19 (except: azithromycin or corticosteroids)
Uncontrolled arterial hypertension;
Current or previous use of systemic immunosuppressive therapy in the last 30 days;
Pregnancy or lactation;
Estimated creatinine clearance \< 30 mL/min or receiving CRRT or intermittent hemodialysis;
Allergy to ruxolitinib;
Active tuberculosis;
HIV seropositivity;
Prior history of progressive multifocal leukoencephalopathy;
Use of any JAK inhibitor in the last 30 days before study enrollment;
Not qualifying according to investigators' perception.

The record

StatusTerminated

PhasePhase 2–3

Taking part5

StartedAug 2020

UpdatedApr 8, 2021

Conditions

Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV2

Where1

Hospital das Clínicas
São Paulo, Brazil

Clareo Health | Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19